Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study

International Journal of Cardiology

Volumn 228, Issue , 2017, Pages 1007-1014

  Lee, Yen Chieh ^a   Chang, Chia Hsuin ^b,c   Dong, Yaa Hui ^d   Lin, Jou Wei ^c   Wu, Li Chiu ^b   Hwang, Jing Shiang ^e   Chuang, Lee Ming ^b,c  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

Author keywords

Acarbose; Glinides; Heart failure; Sulfonylurea

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOTOXIN; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MITIGLINIDE; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STEROID; SULFONYLUREA; ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DISEASE DURATION; DRUG USE; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; ICD-9-CM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; TIME TO TREATMENT; TREATMENT OUTCOME; AGE; AGED; CONFIDENCE INTERVAL; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; FOLLOW UP; HOSPITAL MORTALITY; HOSPITALIZATION; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TAIWAN;

ACARBOSE; ADMINISTRATION, ORAL; AGE FACTORS; AGED; CARBAMATES; COHORT STUDIES; CONFIDENCE INTERVALS; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PIPERIDINES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; SULFONYLUREA COMPOUNDS; SURVIVAL RATE; TAIWAN;

EID: 85002045820     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.022     Document Type: Article

References (45)

1. [1] Nichols, G.A., Gullion, C.M., Koro, C.E., Ephross, S.A., Brown, J.B., The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27 (2004), 1879–1884.
2. [2] Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur. Heart J. 36 (2015), 2288–2296.
3. [3] Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
4. [4] Hirshberg, B., Katz, A., Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care 36:Suppl. 2 (2013), S253–S258.
5. [5] Kumar, R., Kerins, D.M., Walther, T., Cardiovascular safety of anti-diabetic drugs. EHJ Cardiovasc. Pharmacother., 2015.
6. [6] Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet.366:1279-89.
7. [7] Lincoff, A., Wolski, K., Nicholls, S.J., Nissen, S.E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007), 1180–1188.
8. [8] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369 (2013), 1317–1326.
9. [9] Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373 (2015), 232–242.
10. [10] Scirica, B.M., The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure. JAMA Cardiol., 2016.
11. [11] Tomai, F., Crea, F., Gaspardone, A., Versaci, F., De Paulis, R., de Peppo A, P., et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K + channel blocker. Circulation 90 (1994), 700–705.
12. [12] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet, 352, 1998, 837–853.
13. [13] Kahn, S.E., Haffner, S.M., Heise, M.A., Herman, W.H., Holman, R.R., Jones, N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 (2006), 2427–2443.
14. [14] Garratt, K.N., Brady, P.A., Hassinger, N.L., Grill, D.E., Terzic, A., Holmes, D.R. Jr., Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J. Am. Coll. Cardiol. 33 (1999), 119–124.
15. [15] Simpson, S.H., Majumdar, S.R., Tsuyuki, R.T., Eurich, D.T., Johnson, J.A., Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174 (2006), 169–174.
16. [16] Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab. Res. Rev. 23 (2007), 479–484.
17. [17] Khalangot, M., Tronko, M., Kravchenko, V., Kovtun, V., Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res. Clin. Pract. 86 (2009), 247–253.
18. [18] Pantalone, K.M., Kattan, M.W., Yu, C., Wells, B.J., Arrigain, S., Jain, A., et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 33 (2010), 1224–1229.
19. [19] Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36 (2013), 1304–1311.
20. [20] Schramm, T.K., Gislason, G.H., Vaag, A., Rasmussen, J.N., Folke, F., Hansen, M.L., et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. 32 (2011), 1900–1908.
21. [21] Derosa, G., Mugellini, A., Ciccarelli, L., Crescenzi, G., Fogari, R., Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin. Ther. 25 (2003), 472–484.
22. [22] Rizzo, M.R., Barbieri, M., Grella, R., Passariello, N., Barone, M., Paolisso, G., Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. Diabete Metab. 30 (2004), 81–89.
23. [23] Rizzo, M.R., Barbieri, M., Grella, R., Passariello, N., Paolisso, G., Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabete Metab. 31 (2005), 255–260.
24. [24] Derosa, G., Mugellini, A., Ciccarelli, L., Crescenzi, G., Fogari, R., Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res. Clin. Pract. 60 (2003), 161–169.
25. [25] Holman, R.R., Haffner, S.M., McMurray, J.J., Bethel, M.A., Holzhauer, B., Hua, T.A., et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362 (2010), 1463–1476.
26. [26] Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 359:2072-7.
27. [27] Chiasson, J.-L., Josse, R.G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003), 486–494.
28. [28] Saczynski, J.S., Andrade, S.E., Harrold, L.R., Tjia, J., Cutrona, S.L., Dodd, K.S., et al. Mini-sentinel systematic evaluation of health outcome of interest definitions for studies using administrative and claims data: heart failure. Pharmacoepidemiol. Drug Saf., 2012, 21, 10.1002/pds.2313.
29. [29] Austin, P.C., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46 (2011), 399–424.
30. [30] Stürmer, T., Rothman, K.J., Avorn, J., Glynn, R.J., Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study. Am. J. Epidemiol, 2010.
31. [31] Schneeweiss, S., Rassen, J.A., Glynn, R.J., Avorn, J., Mogun, H., Brookhart, M.A., High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20 (2009), 512–522.
32. [32] Schneeweiss, S., Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol. Drug Saf. 15 (2006), 291–303.
33. [33] Bowling, C.B., Feller, M.A., Mujib, M., Pawar, P.P., Zhang, Y., Ekundayo, O.J., et al. Relationship between stage of kidney disease and incident heart failure in older adults. Am. J. Nephrol. 34 (2011), 135–141.
34. [34] Kottgen, A., Russell, S.D., Loehr, L.R., Crainiceanu, C.M., Rosamond, W.D., Chang, P.P., et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J. Am. Soc. Nephrol. 18 (2007), 1307–1315.
35. [35] Gromada, J., Dissing, S., Kofod, H., FrØkjÆr-Jensen, J., Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in Β TC3 cells and rat pancreatic beta cells. Diabetologia 38 (1995), 1025–1032.
36. [36] Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
37. [37] Bennett, W.L., Maruthur, N.M., Singh, S., Segal, J.B., Wilson, L.M., Chatterjee, R., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann. Intern. Med. 154 (2011), 602–613.
38. [38] Ceriello, A., Taboga, C., Tonutti, L., Giacomello, R., Stel, L., Motz, E., et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 39 (1996), 469–473.
39. [39] Ceriello, A., Bortolotti, N., Falleti, E., Taboga, C., Tonutti, L., Crescentini, A., et al. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care 20 (1997), 194–197.
40. [40] Hanefeld, M., Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc. Diabetol., 6, 2007, 20.
41. [41] Hanefeld, M., Cagatay, M., Petrowitsch, T., Neuser, D., Petzinna, D., Rupp, M., Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur. Heart J. 25 (2004), 10–16.
42. [42] Chang, Y.C., Chuang, L.M., Lin, J.W., Chen, S.T., Lai, M.S., Chang, C.H., Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with type 2 diabetes: a nationwide cohort study. Diabet. Med. 32 (2015), 1460–1469.
43. [43] Eurich, D.T., McAlister, F.A., Blackburn, D.F., Majumdar, S.R., Tsuyuki, R.T., Varney, J., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ, 335, 2007.
44. [44] Pazin-Filho, A., Kottgen, A., Bertoni, A.G., Russell, S.D., Selvin, E., Rosamond, W.D., et al. HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 51 (2008), 2197–2204.
45. [45] Boonman-de Winter, L.J., Rutten, F.H., Cramer, M.J., Landman, M.J., Zuithoff, N.P., Liem, A.H., et al. Efficiently screening heart failure in patients with type 2 diabetes. Eur. J. Heart Fail. 17 (2015), 187–195.